Catalyst
Slingshot members are tracking this event:
Kite Pharma (KITE) Opens Enrollment in Phase 2 Portion of ZUMA-1 Assessing KTE-C19 in Patients With Refractory Aggressive Non-Hodgkin's Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Zuma-1, Kte-c19, Refractory Agressive Non-hodgkin's Lymphoma
